



**FOR IMMEDIATE RELEASE**

## **Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference**

*Heidelberg, Germany, January 4, 2019* - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:30 a.m. Pacific Time / 2:30 p.m. Eastern Time.

A live webcast of the presentation can be accessed under the "News & Events" section of Affimed's website at <https://www.affimed.com/investors/webcasts/> and will be available for 30 days following the event.

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed's fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers. For more information, please visit [www.affimed.com](http://www.affimed.com).

### **Affimed Investor Contact:**

Gregory Gin, Head of Investor Relations  
E-Mail: [IR@affimed.com](mailto:IR@affimed.com)

### **Affimed Media Contact:**

Anca Alexandru, Head of Communications, EU IR  
E-Mail: [media@affimed.com](mailto:media@affimed.com)